key: cord-0892208-t6rs1i7b
authors: Garcia, Felipe Perez; Perez Tanoira, Ramon; Romanyk Cabrera, Juan Pedro; Arroyo Serrano, Teresa; Gomez Herruz, Peña; Cuadros Gonzalez, Juan
title: Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM antibodies with an immunochromatographic device: a prospective single-center study
date: 2020-04-15
journal: nan
DOI: 10.1101/2020.04.11.20062158
sha: 2e9a14f52eb510e67b97ac68b6649a1a2eac3f22
doc_id: 892208
cord_uid: t6rs1i7b

Objectives: SARS-CoV-2 infection constitutes a diagnostic challenge in patients from 2-3 weeks after the onset of symptoms, due to the low positivity rate of the PCR, especially in upper respiratory samples. Serologic tests based on ELISA have been developed and evaluated as useful complements to PCR in these situations. However, there is scarce information about the usefulness of rapid tests based on immunochromatography. The aim of our study was to analyze the diagnostic performance of these rapid tests in COVID-19 pneumonia patients. Methods: We evaluated an immunochromatographic test (AllTest COV-19 IgG / IgM kit) which detects IgG and IgM antibodies. First, we performed a validation of the serologic test using serum samples from 45 healthy control patients (group 1) and 55 confirmed by PCR cases of COVID-19 (group 2) in order to establish the specificity and sensitivity, respectively. Then we prospectively employed the test in 63 patients diagnosed with pneumonia of unknown etiology that were SARS-CoV-2 negative by PCR (group 3), to establish the diagnostic performance in these patients. Results: All patients from group 1 (healthy controls) resulted negative for the serologic test (specificity = 100%). Regarding group 2 (PCR positive) patients, the median time from the onset of symptoms was 11 days and the test was positive for either IgM or IgG in 26 out of 55 patients (overall sensitivity = 47.3%). However, in those patients with 14 days or more from onset of symptoms, the sensitivity was 73.9%. Regarding group 3 patients, the median days from onset of symptoms was 17 and the test was positive in 56 out of 63 patients (88.9% positivity rate). In these group 3 patients with 14 days or more from onset of symptoms, the positivity rate was 91.1%. Conclusions: Our study shows that serologic rapid tests can be used as a complement of PCR to diagnose SARS-CoV-2 infection after 14 days from the onset of symptoms. These immunochromatographic devices could be especially useful in hospitalized patients with pneumonia of unknown etiology with 14 or more days from the onset of symptoms and in whom the PCR has been negative.

The pandemic due to SARS-CoV-2 that started in Wuhan four months ago (1, 2) has caused until April 8th a total of 1,353,361 cases and 79,235 deaths worldwide (3) . Spain is the country of the European region that has been most affected by the infection, accounting for 140,510 cases and 13,798 deaths by April 8th (3) . From the beginning of the pandemic, one of the main concerns to deal with was the complexity and excessive time to results of the diagnostic test, based on polymerase chain reaction (PCR). Few clinical microbiology laboratories were prepared at this time to process such a massive volume of samples that grew exponentially. In our hospital, which is a middle sized center (440 beds), from March 5th to April 6th, a total of 7,453 respiratory samples (the vast majority nasopharyngeal exudates) were processed for SARS-CoV-2 PCR, reaching a positivity rate between 20 and 40%. Another added problem was the low positivity rate of nasopharyngeal samples in patients presenting a clinical syndrome compatible with COVID-19 in the second and third week of infection (1, 4) , which is generally the period in which patients get worse and are admitted to the hospital (1). On the other hand, most patients present a non-productive cough (5); this fact, together with the high risk of generating aerosols in bronchoscopies explains that most respiratory samples came from the upper respiratory tract, where the virus concentration is lower beyond the first week after the onset of symptoms (6,7). As a consequence, the positivity rate of the PCR in these patients could be lower than expected and many of them were hospitalized with a provisional diagnosis of pneumonia of unknown etiology and possible COVID-19.

In order to overcome these limitations, different microplate ELISA tests have been developed. Recently published studies confirm the usefulness of combining PCR in nasopharyngeal exudates and the detection of IgM and IgG antibodies in the blood of patients (8). The combination of both molecular and serologic techniques allowed some authors to achieve a sensitivity of 97% for diagnosis of SARS-CoV-2 infection (9). However, these tests based on ELISA are not as suitable for clinical use as rapid tests because they are time-consuming and, as a matter of fact, cannot be included in the management algorithms in emergency departments (8,9). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2020. .

Since the beginning of the epidemic in Spain, we received information about the availability of rapid serological diagnostic kits that detected IgG and IgM antibodies using immunochromatographic (ICT) devices. However, there are very few published studies about the clinical application of these kits (10). The aim of our study was to evaluate the diagnostic performance of one of these serologic rapid tests, first by a validation of the test in healthy patients and confirmed cases of COVID-19 and then by a prospective evaluation in patients with pneumonia of unknown etiology and a clinical diagnosis of COVID-19 with negative PCR for SARS-CoV-2.

We included 3 groups of patients in our study: Group 3 (pneumonia of unknown etiology): patients who had been admitted for at least 5 days between February 9 and April 2, 2020, with a clinical and radiological diagnosis of pneumonia of unknown etiology, in which the PCR for SARS-CoV-2 was negative. They were prospective studied after the validation of the serologic test.

Molecular techniques: Two automatic extractors were used to obtain viral RNA from clinical samples:

MagCore HF16 (RBC bioscience, Taipei, Taiwan) and Hamilton Microlab Starlet (Hamilton Company, Bonaduz, Switzerland). RNA amplification was made using two real-time PCR platforms: VIASURE SARS-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Group 1 (healthy controls); Group 2 (PCR positive); Group 3 (pneumonia of unknown etiology and negative PCR). IQR: interquartile range; PCR: polymerase chain reaction.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2020. . https://doi.org/10.1101/2020.04.11.20062158 doi: medRxiv preprint

All patients included in the group 1 showed negative results for serological tests. Thus, the serological test presented a specificity of 100%. The overall sensitivity of the test was 47.3% compared to PCR (Table 1 ).

An increase in sensitivity was found after seven days from onset of symptoms (p=0.033), and as the days with symptoms progressed (p≤0.001) (Figure 1 ). However a reduction was detected in the fourth week (53.8%) compared to third week (83.3%), not being statistically significant (p=0.333). After the fourth week, the positivity rate for IgG antibodies increased, thus reaching a positivity rate of 100%.

We assessed the serologic test in the group 3 patients. Antibodies against SARS-CoV-2 were detected in 56 out of 63 patients (88.9%), being 100% of them positive for IgG antibodies, and 39.7% positive also for IgM antibodies (Table 1) . No patient had less than 7 days from onset of symptoms. The positivity rate increased from 7-13 days (83.3%) to ≥14 days (91.1%), but there were no statistically significant differences between weeks (p=0.087) (Table 1 & Figure 1 ). In a similar way as group 2 patients, we observed a slight decrease in the positivity rate in the fourth week after onset of symptoms for IgG antibodies (73.3%) (p=0.260), and after the fourth week, the positivity rate for IgG antibodies increased, thus reaching a positivity rate of 100% ( Figure 1 ). 

Clinical Characteristics of Coronavirus Disease 2019 in China

The COVID-19 Pandemic in the US: A Clinical Update

Novel Coronavirus (2019-nCoV) situation reports